Related references
Note: Only part of the references are listed.Population pharmacokinetics of ramosetron
Seong Heon Lee et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2016)
Association of 5-HT3B Receptor Gene Polymorphisms with the Efficacy of Ondansetron for Postoperative Nausea and Vomiting
Min-Soo Kim et al.
YONSEI MEDICAL JOURNAL (2015)
A Randomized, Double-Blind Pilot Study of Dose Comparison of Ramosetron to Prevent Chemotherapy-Induced Nausea and Vomiting
Ka-Rham Kim et al.
BIOMED RESEARCH INTERNATIONAL (2015)
Pharmacogenetic predictors of nausea and vomiting of pregnancy severity and response to antiemetic therapy: a pilot study
Amalia S. Lehmann et al.
BMC PREGNANCY AND CHILDBIRTH (2013)
Association of ABCB1, 5-HT3B Receptor and CYP2D6 Genetic Polymorphisms with Ondansetron and Metoclopramide Antiemetic Response in Indonesian Cancer Patients Treated with Highly Emetogenic Chemotherapy
Dyah A. Perwitasari et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2011)
Evidence-based recommendations for cancer nausea and vomiting
Arash Naeim et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Drug therapy: Chemotherapy-induced nausea and vomiting
Paul J. Hesketh
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Naturally occurring variants in the HTR3B gene significantly alter properties of human heteromeric 5-hydroxytryptamine-3A/B receptors
Jutta Walstab et al.
PHARMACOGENETICS AND GENOMICS (2008)
Guidelines for antiemetic treatment of chemotherapy-induced nausea and vomiting: Past, present, and future recommendations
Karin Jordan et al.
ONCOLOGIST (2007)
The 5-HT3 receptor as a therapeutic target
Andrew J. Thompson et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2007)
The impact of pharmacogenomics on postoperative nausea and vomiting - Do CYP2D6 allele copy number and polymorphisms affect the success or failure of ondansetron prophylaxis?
KA Candiotti et al.
ANESTHESIOLOGY (2005)
Variations in the 5-hydroxytryptamine type 3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patients
PB Tremblay et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Contribution of P-glycoprotein to efflux of ramosetron, a 5-HT3 receptor antagonist, across the blood-brain barrier
C Yamamoto et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2002)
Molecular genetics of CYP2D6:: Clinical relevance with focus on psychotropic drugs
L Bertilsson et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2002)
Ramosetron, a 5-HT3 receptor antagonist for the control of nausea and vomiting
X Rabasseda
DRUGS OF TODAY (2002)
5-HT3-receptor antagonists for the treatment of nausea and vomiting: A reappraisal of their side-effect profile
S Goodin et al.
ONCOLOGIST (2002)
Share Paper
